Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin s...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
- Associated Therapies
- -
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Xiuli Zuo
- Target Recruit Count
- 30
- Registration Number
- NCT06731023
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 248
- Registration Number
- NCT06709196
- Locations
- 🇩🇰
Department of Urology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Urology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Department of Urology, Rigshospitalet, Copenhagen, Denmark
Evaluation of the Effect of Antibiotic Prophylaxis (2g Amoxicillin One Hour Before Surgery) on an Inflammatory Factor (PGE2) in Salivary Samples After Third Molars Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Universidad Católica San Antonio de Murcia
- Target Recruit Count
- 18
- Registration Number
- NCT06613776
- Locations
- 🇪🇸
UCAM dental, Clinica odontologica universitaria, Murcia, Spain
Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 548
- Registration Number
- NCT06603688
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xian, Shaanxi, China
High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT06561698
- Locations
- 🇨🇳
Hebi People's Hospital, Hebi, Henan, China
🇨🇳Jiaozuo People's Hospital, Jiaozuo, Henan, China
🇨🇳Luoyang central Hospital, Luoyang, Henan, China
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 208
- Registration Number
- NCT06523764
Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 558
- Registration Number
- NCT06514274
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 236
- Registration Number
- NCT06494072
- Locations
- 🇺🇸
Childrens Wisconsin, Milwaukee, Wisconsin, United States
Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Soonchunhyang University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06431737
- Locations
- 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of
Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 268
- Registration Number
- NCT06412640
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.